IL122174A - דנ" א המקודד למוטאין cd40l ופוליפפטיד cd40l המקודד ע" י הדנ" א הנ" ל - Google Patents

דנ" א המקודד למוטאין cd40l ופוליפפטיד cd40l המקודד ע" י הדנ" א הנ" ל

Info

Publication number
IL122174A
IL122174A IL12217496A IL12217496A IL122174A IL 122174 A IL122174 A IL 122174A IL 12217496 A IL12217496 A IL 12217496A IL 12217496 A IL12217496 A IL 12217496A IL 122174 A IL122174 A IL 122174A
Authority
IL
Israel
Prior art keywords
cd40l
dna
leu
seq
ser
Prior art date
Application number
IL12217496A
Other languages
English (en)
Other versions
IL122174A0 (en
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/484,624 external-priority patent/US5962406A/en
Priority claimed from US08/477,733 external-priority patent/US5981724A/en
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of IL122174A0 publication Critical patent/IL122174A0/xx
Publication of IL122174A publication Critical patent/IL122174A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
IL12217496A 1995-06-07 1996-06-06 דנ" א המקודד למוטאין cd40l ופוליפפטיד cd40l המקודד ע" י הדנ" א הנ" ל IL122174A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/484,624 US5962406A (en) 1991-10-25 1995-06-07 Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US08/477,733 US5981724A (en) 1991-10-25 1995-06-07 DNA encoding CD40 ligand, a cytokine that binds CD40
PCT/US1996/009632 WO1996040918A2 (en) 1995-06-07 1996-06-06 Novel cd40l mutein

Publications (2)

Publication Number Publication Date
IL122174A0 IL122174A0 (en) 1998-04-05
IL122174A true IL122174A (he) 2004-07-25

Family

ID=27045653

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12217496A IL122174A (he) 1995-06-07 1996-06-06 דנ" א המקודד למוטאין cd40l ופוליפפטיד cd40l המקודד ע" י הדנ" א הנ" ל

Country Status (15)

Country Link
EP (1) EP0832229B1 (he)
JP (1) JP3279573B2 (he)
KR (1) KR100453314B1 (he)
AT (1) ATE257858T1 (he)
AU (1) AU693713B2 (he)
CA (1) CA2222914C (he)
DE (1) DE69631331T2 (he)
DK (1) DK0832229T3 (he)
ES (1) ES2214541T3 (he)
IL (1) IL122174A (he)
MX (1) MX9709447A (he)
NO (1) NO317735B1 (he)
NZ (1) NZ311335A (he)
PT (1) PT832229E (he)
WO (1) WO1996040918A2 (he)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
NZ333607A (en) * 1996-07-10 2000-08-25 Immunex Corp Method of stimulating the immune system by transfecting dendritic cells
DE69738841D1 (de) 1996-12-23 2008-08-28 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
EP2009025B1 (en) * 1998-05-14 2011-07-27 Immunex Corporation Method of inhibiting osteoclast activity
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
PL232477B1 (pl) 2001-09-20 2019-06-28 Immunex Corp System ekspresji gospodarza i sposób wytwarzania heteromerycznego kompleksu
WO2004074439A2 (en) 2003-02-14 2004-09-02 Biogen Idec Ma Inc. An expression cassette and vector for transient or stable expression of exogenous molecules
JP3936673B2 (ja) * 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
EP1673389A2 (en) * 2003-10-10 2006-06-28 Xencor Inc. Novel variants of cd40l protein
JP5553963B2 (ja) 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
EP2500415A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
EP2517723B1 (en) 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Compositions and methods of enhancing immune responses
WO2009005140A1 (ja) * 2007-06-29 2009-01-08 Asubio Pharma Co., Ltd. 組換えＣ－末端α－アミド化酵素誘導体
MX2010002683A (es) 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
BRPI0818736A2 (pt) 2007-10-30 2017-06-13 Univ Arkansas composições e métodos para intensificar imunorrepostas à bactéria flagelada
HUE047164T2 (hu) 2007-11-01 2020-04-28 Univ Arkansas Kompozíciók és eljárások eimeria elleni immunválasz fokozására
KR20100113112A (ko) 2008-01-15 2010-10-20 아보트 러보러터리즈 개선된 포유동물 발현 벡터 및 이의 용도
EP3255153A1 (en) 2009-11-17 2017-12-13 E. R. Squibb & Sons, L.L.C. Methods for enhanced protein production
EP2525817B8 (en) 2010-01-21 2017-09-20 The Board of Trustees of The University of Arkansas Vaccine vectors and methods of enhancing immune responses
HUE046858T2 (hu) 2010-06-09 2020-03-30 Univ Arkansas Vakcina és eljárások campylobacter fertõzés csökkentésére
MY173328A (en) 2013-02-14 2020-01-16 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
EA033538B1 (ru) 2013-03-15 2019-10-31 Univ Arkansas Композиции и способы усиления иммунного ответа на кишечные патогены
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
TWI758288B (zh) 2016-05-03 2022-03-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
KR102439719B1 (ko) 2016-05-11 2022-09-02 암젠 인크 글루타민 합성효소 유전자내 상보성 벡터를 사용한 높은 수준의 헤테로머 단백질을 발현하는 세포의 직접적인 선택
CN109153729A (zh) * 2016-05-13 2019-01-04 免疫医疗有限责任公司 Cd40l-fc融合多肽及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3308534B2 (ja) * 1991-10-25 2002-07-29 イミュネックス・コーポレーション 新規なサイトカイン
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
DE69332981T2 (de) * 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine

Also Published As

Publication number Publication date
AU6263896A (en) 1996-12-30
MX9709447A (es) 1998-02-28
NO317735B1 (no) 2004-12-13
NO975437L (no) 1998-02-06
CA2222914A1 (en) 1996-12-19
ES2214541T3 (es) 2004-09-16
NO975437D0 (no) 1997-11-26
JP3279573B2 (ja) 2002-04-30
DE69631331D1 (de) 2004-02-19
DK0832229T3 (da) 2004-05-03
JPH11504819A (ja) 1999-05-11
WO1996040918A3 (en) 1997-01-23
DE69631331T2 (de) 2004-11-18
EP0832229B1 (en) 2004-01-14
KR100453314B1 (ko) 2004-12-17
NZ311335A (en) 1998-05-27
IL122174A0 (en) 1998-04-05
CA2222914C (en) 2002-04-02
EP0832229A2 (en) 1998-04-01
WO1996040918A2 (en) 1996-12-19
PT832229E (pt) 2004-06-30
KR19990022141A (ko) 1999-03-25
AU693713B2 (en) 1998-07-02
ATE257858T1 (de) 2004-01-15

Similar Documents

Publication Publication Date Title
AU693713B2 (en) CD40L mutein
US6264951B1 (en) Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L
US6290972B1 (en) Method of augmenting a vaccine response by administering CD40 ligand
MXPA97009447A (en) New muteina cd
AU661360B2 (en) Novel cytokine
US5961974A (en) Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
Nakamura et al. Heterodimerization of the IL-2 receptor β-and γ-chain cytoplasmic domains is required for signalling
US6165476A (en) Fusion proteins with an immunoglobulin hinge region linker
EP1229047B1 (en) IL-1 Receptor fusion proteins used as antagonists and methods of making and using
US5488032A (en) Method of using soluble human interleukin-1 receptors to suppress inflammation
US20030144182A1 (en) CD40-Ligand lacking native-pattern glycosylation
USRE35450E (en) Soluble human interleukin-1 receptors, compositions and method of use
ES et al. NEUE CYTOKINE NOUVELLE CYTOKINE

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees